Researchers engineered a chimeric peptide combining rabies virus glycoprotein and snake toxin sequences that selectively targets alpha-7 nicotinic receptors to deliver cargo into brain cells.
Improved α7 selectivity over standard RVGThe chimeric peptide showed better alpha-7 nicotinic receptor subtype selectivity and potency than the widely used rabies virus glycoprotein peptide
What the researchers found
The researchers designed chimeric peptides combining regions of rabies virus glycoprotein (RVG) and alpha-bungarotoxin, then screened them for receptor selectivity. They identified a peptide with improved selectivity and apparent potency for the alpha-7 nicotinic acetylcholine receptor (nAChR) subtype compared to the control RVG peptide. In Neuro-2a cells, the peptide's internalization depended on alpha-7 nAChR expression on the cell surface, and it successfully carried small-molecule payloads into neuronal-like cells without significant cytotoxic effects.
Why it matters
Current brain drug delivery peptides lack target specificity, meaning they spread throughout the brain and cause off-target side effects. A peptide that selectively uses alpha-7 nicotinic receptors as its entry point could enable more precise delivery of therapeutics to specific brain cell populations. Alpha-7 nAChRs are implicated in Alzheimer's disease, schizophrenia, and other neurological conditions, making this a strategically important target for dual-purpose drug delivery.
How the study worked
Researchers designed several chimeric peptides and tested their selectivity using human nicotinic acetylcholine receptors expressed in Xenopus laevis oocytes with two-electrode voltage clamp electrophysiology — a technique that measures receptor responses to peptide binding. They then tested the lead peptide's ability to enter cells and deliver cargo using mammalian Neuro-2a cells (a neuronal cell line), assessing internalization, payload delivery, and cytotoxicity.
What this study cannot tell us
This is a preprint (bioRxiv) that has not yet been peer-reviewed. All experiments were conducted in vitro using frog oocytes and a neuronal cell line — there are no in vivo blood-brain barrier crossing data. The small-molecule cargo delivery was demonstrated but therapeutic payloads were not tested. Whether the selectivity observed in controlled cell systems translates to the complex environment of the intact brain remains unknown.
How to read the evidence
This is a preprint reporting early-stage in vitro work with cell lines and oocyte expression systems. While the approach is innovative, no in vivo or blood-brain barrier data exist yet. Evidence grade is preliminary/preclinical.
When this study was published
Published as a 2025 bioRxiv preprint, this is cutting-edge research that has not yet undergone peer review. Findings should be considered preliminary.
The bigger picture
Peptide-based drug delivery to the brain is a rapidly growing field as researchers seek alternatives to invasive methods for crossing the blood-brain barrier. This work represents a step toward precision brain drug delivery — using engineered peptides that don't just get into the brain, but target specific receptor types once there. If the alpha-7 selectivity holds in vivo, this approach could enable targeted therapies for diseases where alpha-7 nAChR-expressing neurons are specifically affected.
Questions still open
- Can this chimeric peptide actually cross the blood-brain barrier in living animals while maintaining its alpha-7 selectivity?
- Could this approach be adapted to target other specific receptor subtypes for precision brain drug delivery?
- What types of therapeutic cargo — beyond small molecules — could this peptide system deliver to the brain?
Common questions
What is a cell-penetrating peptide and how does it get drugs into the brain?
Why is targeting a specific receptor important for brain drug delivery?
Read the original research
Development of a novel alpha7-nicotinic acetylcholine receptor-selective cell-penetrating peptide for intracellular cargo transport.
bioRxiv : the preprint server for biology
Citation
Weber, Lahra; O'Brien, Brittany C V; Weltzin, Maegan M. (2025). Development of a novel alpha7-nicotinic acetylcholine receptor-selective cell-penetrating peptide for intracellular cargo transport.. bioRxiv : the preprint server for biology. https://doi.org/10.1101/2025.08.08.669423